

NOTICE REQUIRED UNDER ASX LISTING RULE 3.13.1

Melbourne, Australia, 27 September 2023: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) advises that the Annual General Meeting (AGM) is scheduled for 28 November 2023. The closing date for the receipt of nominations from persons wishing to be considered for election as a director of the Company is 5 October 2023. Any nominations must be received in writing no later than 5.00pm (AEDT) on 5 October 2023 at the Company's registered office.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting which will be provided in due course.

Authorised by the Company Secretary, Mark Edwards.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising next-generation exosome capture tools and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO-NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. For more information on INOVIQ, [see www.inoviq.com](http://www.inoviq.com).